Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments?
Takimoto
Chris H
CH
Institute for Drug Development, Cancer Therapy and Research Center, Alice P McDermott Building, San Antonio, TX 78245-3217, USA. ctakimot@idd.org